Superior overall survival with blinatumomab versus chemotherapy as pre-transplant consolidation treatment in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia (B-ALL): longer follow-up (FU) of a Phase 3 randomized controlled trial (RCT)
Authors
Focatelli, F.Zugmaier, G.
Rizzari, C.
Dorris, J. D.
Gruhn, B.
Klingebie, T.
Parasole, R.
Linderkamp, C.
Flotho, C.
Petit, A.
Micalizzi, C.
Zeng, Y.
Pilankar, D. D.
Kormany, W. N.
Eckert, C.
Moericke, A.
Sartor, M.
Hrusak, O.
Peters, C.
Saha, Vaskar
Vinti, L.
Stackelberg, A.
Affiliation
Department of Hematology/Oncology and Cell and Gene Therapy, Bambino Gesù Children's Hospital, Sapienza, University of Rome, RomeIssue Date
2021
Metadata
Show full item recordCitation
Focatelli F, Zugmaier G, Rizzari C, Dorris JD, Gruhn B, Klingebie T, et al. Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398804255.Journal
BloodDOI
10.1182/blood-2021-145476Additional Links
https://dx.doi.org/10.1182/blood-2021-145476Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-145476